Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Abstract: Salient object detection (SOD) pre-processes downstream computer vision tasks. Based on the Saliency and Detail Map Interactive Model for Salient Region Detection, we constructed detail maps ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results